# Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-da-23-021-developing-regulated-therapeutic-and-diagnostic-solutions/  
Official notice: https://www.grants.gov/search-results-detail/338989

> National Institutes of Health offered grants to small businesses. Applications closed on February 14, 2025.

| Field | Value |
|---|---|
| Opportunity number | RFA-DA-23-021 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | February 14, 2025 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.279 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and stimulant use disorders (StUD). Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics; and (2) medical therapeutic and diagnostic devices, including software as a medical device. This FOA strives to contribute to the effort against national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis.

## Questions people ask

### Is RFA-DA-23-021 still open?

No. It closed on February 14, 2025.

### Who can apply for Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)?

Closed February 14, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-DA-23-021?

NIH RePORTER lists 40 projects funded under RFA-DA-23-021 in fiscal 2023 to 2026, at 38 institutions. The most were at Instanosis, Inc., Autonomous Healthcare, Inc., Wavi Company.

### Who has won Drug Use and Addiction Research Programs grants before?

The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.